Get the Stockscreener App
91.07
0.32%
0.29
After Hours:
90.75
-0.32
-0.35%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $91.07, with a volume of 11.88M.
It is up +0.32% in the last 24 hours and up +4.47% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$90.78
Open:
$91.75
24h Volume:
11.88M
Relative Volume:
0.95
Market Cap:
$158.63B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
25.37
EPS:
3.5895
Net Cash Flow:
$7.38B
1W Performance:
+6.39%
1M Performance:
+4.47%
6M Performance:
-27.19%
1Y Performance:
-32.01%
1-Day Range:
$90.95
$92.73
1-Week Range:
$85.60
$92.73
52-Week Range:
$81.97
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
91.07 | 158.12B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.66 | 115.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
81.67 | 105.19B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
48.55 | 72.61B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.96 | 50.35B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Says Timing Mismatch Lets $8B Gain Go Untaxed - Law360
What is Abbott Tokenized Stock (Ondo)(ABTON) Coin? A comprehensive guide you shouldn’t miss - WEEX
A Grandma Bought PediaSure To Help Her Grandson Grow — Now, Abbott Is In Federal Court - Benzinga
Chemiluminescence Immunoassay Market Expected to Reach USD 16.39 Billion by 2031 | MarketsandMarkets™ - GlobeNewswire Inc.
Abbott Laboratories stock is getting decimated, but the smart money senses opportunity - MSN
Better medical device stock right now: Abbott Laboratories vs. Dexcom - MSN
Is It Too Late to Buy Abbott Laboratories (ABT) After 4.4% Rally? GF Value Says Undervalued - GuruFocus
Judge Questions Fees In Abbott Investors' $40M Formula Deal - Law360
Abbott Can’t Drop PediaSure Children’s Growth Deception Suit - Bloomberg Law News
Abbott Labs must face lawsuit over PediaSure children's growth claims - Reuters
Abbott Labs must face lawsuit over PediaSure children’s growth claims - The Mighty 790 KFGO
Abbott Laboratories Stock (ABT) Closed Up by 4.18% on Jun 4: Drivers Behind the Movement - TradingKey
Abbott Laboratories stock (US0028241000): shares advance on strong US trading - AD HOC NEWS
[Latest] Non-Invasive Blood Glucose Monitoring Devices Market Size to Hit USD 340.49 Million with a Promising CAGR of 25.60% by 2034 - GlobeNewswire Inc.
Abbott Laboratories stock gains as Norges Bank acquires new institutional position - Traders Union
Abbott Laboratories shares jump as stock buying pressure builds - Traders Union
Abbott shares rise as investors refocus on diabetes tech and cancer-diagnostics momentum - Quiver Quantitative
Abbott Laboratories on Pace for Largest Percent Increase Since April 2023 -- Data Talk - Moomoo
Abbott Addresses a Major Diabetes Care Gap With Tech Innovation - Yahoo Finance
Jim Cramer Says “No One Disputes the Science and Commercial Smarts of Abbott” - Insider Monkey
Abbott Pakistan’s profit surge masks a volume problem - Profit by Pakistan Today
Assessing Abbott Laboratories (ABT) Valuation After New Diabetes Sensor And Cancer Screening Tailwinds - Yahoo Finance
Abbott Laboratories stock (US0028241000): U.S. healthcare name steadies after recent slide as instit - AD HOC NEWS
MiniMed expands Abbott partnership to add dual glucose-ketone sensor - MedTech Dive
Is Abbott Laboratories stock underperforming the Dow? - MSN
MiniMed Shares Rise on 4Q Sales, Abbott Partnership Expansion - marketscreener.com
Abbott (ABT) Expands Collaboration with MiniMed for Innovative G - GuruFocus
MiniMed partners with Abbott on dual glucose-ketone sensors By Investing.com - Investing.com Canada
Abbott Laboratories Deadline Alert - TMX Newsfile
Abbott India Ltd. Faces Bearish Momentum Amid Technical Downgrade - Markets Mojo
How A Steady Valuation Is Shaping The Evolving Abbott Laboratories (ABT) Investment Story - Yahoo Finance
Abbott Laboratories stock (US0028241000): shares edge higher ahead of Q2 2026 earnings after guidanc - AD HOC NEWS
Is Abbott Laboratories (ABT) Now Attractive After A 33% One Year Share Price Slide - simplywall.st
Why Investors Are Cautious on Abbott Laboratories (ABT) - Insider Monkey
Why Investors Are Cautious on Abbott Laboratories (ABT)? - Yahoo Finance
The demand for healthcare is going to continue to accelerate, says Abbott Labs CEO Robert Ford - MSN
ASCO26: Abbott demonstrates MRD test benefit in TNBC recurrence - Medical Device Network
Peripheral Vascular Devices Market by Type, End User - GlobeNewswire Inc.
Abbott Labs Spinal Cord Device Causes Shocks, Suit Claims - Law360
Tax Havens Cost US $40 Billion After Trump Withdraws From Global Deal - The Fiscal Times
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Goldman Sachs Maintains Abbott Laboratories(ABT.US) With Buy Rating, Cuts Target Price to $113 - Moomoo
Abbott Laboratories stock (US0028241000): shares steady after CE mark win for Libre Duo system - AD HOC NEWS
Precision Trading with Abbott Laboratories (ABT) Risk Zones - Stock Traders Daily
Abbott's CE Mark Win for Libre Duo Systems May Lift Its Stock - Yahoo Finance Australia
Ophthalmology Devices Market Is Going to Boom | Abbott Laboratories, Carl Zeiss AG, CooperVision - openPR.com
Abbott Accused of Firing Manager for Reporting Kickback Schemes - Bloomberg Law News
Abbott Laboratories: Buy Rating Reaffirmed on Improving 2026 Growth Outlook and Margin Expansion Potential, with Price Target Trimmed to $113 - TipRanks
Abbott Laboratories (ABT) Stock Analysis: Exploring a 37% Upside Potential Amidst Healthcare Innovations - DirectorsTalk Interviews
Abbott Laboratories stock (US0028241000): U.S. healthcare name steadies after recent ETF inclusion a - AD HOC NEWS
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):